Illumina, Inc.

Health Care
Medical Specialities
www.illumina.com

Earnings Score
Moat Score

Market Cap $22.43B
PE -14
Debt $NaN
Cash $869.00M
EV $NaN
FCF $547.00M

Earnings

loading chart...

Sales & Net Margins

loading chart...

Earnings	-$1.59B
EBIT	-$1.17B
ROE	-75%
ROA	-19%
FCF	$547.00M
Equity	$2.13B
Growth Stability	-549%
PE	-14.15
PEG	49.98
PB	10.56
P/FCF	41.01
P/S	5.11
Price/Cash	0.04
Net Margins	-43%
Gross Margins	64%
Op. Margins	-27%
Earnings CAGR	1%
Sales Growth YoY	-3%
Sales Growth QoQ	-3%
Sales CAGR	9%
FCF CAGR	-7%
Equity CAGR	14%
Earnings Stability	0.05
Earnings Growth YoY	-193%

Earnings Growth QoQ	-135%
Earnings CAGR 5Y	-0%
Sales CAGR 5Y	7%
FCF CAGR 5Y	-21%
Equity CAGR 5Y	-7%
Earnings CAGR 3Y	-2%
Sales CAGR 3Y	-2%
FCF CAGR 3Y	36%
Equity CAGR 3Y	-44%
Market Cap	$22.43B
Revenue	$4.39B
Assets	$6.01B
Cash	$869.00M
Shares Outstanding	159M
Earnings Score	6%
Moat Score	2%
Working Capital	1.4B
Current Ratio	2.43
Gross Profit	$2.81B
Shares Growth 3y	1%
Equity Growth QoQ	48%
Equity Growth YoY	-64%

Assets & ROA

loading chart...

Stockholders Equity & ROE

loading chart...

Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (less than 10% of sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.

SEC Filings

Direct access to Illumina, Inc. (ILMN) Annual Reports (10K) and Quarterly Reports (10Q) from the SEC website.

2024
- 10-Q Sep 29
- 10-Q Jun 30
- 10-Q Mar 31
2023
- 10-K Dec 31
- 10-Q Oct 01
- 10-Q Jul 02
- 10-Q Apr 02
- 10-K Jan 01
2022
- 10-Q Oct 02
- 10-Q Jul 03
- 10-Q Apr 03
- 10-K Jan 02

Sector Comparison

How does Illumina, Inc. compare to its competitors?

Loading chart...

Peter Lynch's Chart

This chart shows the current pricing of Illumina, Inc. compared to its past. The addition of the earnings trend line provides further insights into the company's earnings power.

CAGR 1%

Stability 5%

loading chart...

Illumina, Inc. Discounted Cash Flow

Fully customizable DCF calculator online for Illumina, Inc..

Years

Calculation mode

= $3.4B

	0	1	2	3	4	5	6	7	8	9	10	TV
fcf	$547M	$506M	$469M	$434M	$402M	$372M	$344M	$318M	$295M	$273M	$253M	$2.5B
DCF		$460M	$387M	$326M	$274M	$231M	$194M	$163M	$137M	$116M	$97M	$974M
Value	$3.4B

Competitiveness and MOAT

High margins render the company resilient under dire circumstances, hence able to drive competitors out or acquire them. ROE and ROA measure the average flow generated by each invested dollar. Their marginal value is a forecast of future growth, and it is considered by Buffett and Munger the most important single indicator.

Years	12/2014	01/2016	12/2016	12/2017	12/2018	12/2019	01/2021	01/2022	12/2022	12/2023	TTM
Net Margins	19%	21%	18%	25%	23%	28%	20%	17%	-96%	-26%	-43%
ROA	-	17%	14%	21%	14%	16%	12%	6%	-34%	-11%	-19%
ROE	-	25%	19%	25%	20%	21%	14%	7%	-67%	-20%	-75%

Bad Net Margins (-43.15%)

Net Margins are too low to guarantee profitability in case of higher costs or higher interest rates. Furthermore lower margins cause higher earnings’ volatility.

Safety and Stability

Being debt the number one cause of investment losses and company death, the ratio Debt/FCF is of utmost importance to guarantee safety. On the other hand the Graham’s stability measures the drawdown of earnings, hence indicating the reliability of the flow generated by the company.

Years	12/2014	01/2016	12/2016	12/2017	12/2018	12/2019	01/2021	01/2022	12/2022	12/2023	TTM
Debt over FCF	-	2.11	2.45	2.11	2.36	1.36	1.33	2.95	21.08	0	-
Debt over Equity	1.21	0.59	0.46	0.43	0.52	0.25	0.25	0.09	0.34	0	-
Growth Stability	-	-	-	100%	100%	100%	80%	94%	-549%	-	-549%

Neutral Debt/FCF ratio (-)

Net Margins are at a level that is not too high nor too low. They are not a competitive advantage but they are not a competitive disadvantage either.

Neutral Debt/Equity ratio (-)

The company has a balance between equity and debt that is not too good nor too bad.

Bad Graham’s Stability (-549%)

The company has a bad stability in its earnings, which is a sign of a bad competitive advantage.

Growth

Growth can be dangerous when forecasting, simply projecting the current growth is in general wrong. A company passes through multiple phases, from being young and unprofitable, to the first periods of profitability and high growth, until it arrives at a period of regime with limited growth. Identifying in which phase the company is in may help forecasting.

Years	12/2014	01/2016	12/2016	12/2017	12/2018	12/2019	01/2021	01/2022	12/2022	12/2023	CAGR 5Y
Revenue YoY growth	-	19%	8%	15%	21%	6%	-9%	40%	1%	-2%	7%
Earnings YoY growth	-	29%	-6%	58%	15%	27%	-34%	16%	-678%	-74%	-0%
Equity YoY growth	-	26%	23%	21%	40%	20%	2%	129%	-39%	-13%	-7%
FCF YoY growth	-	31%	-17%	32%	50%	-0%	6%	-62%	-69%	167%	-21%